Metabolic endoscopy · United Kingdom
Endoluminal sleeve (EndoBarrier) — a UK patient guide.
A 60cm duodenal-jejunal bypass liner for adults with type 2 diabetes and obesity — a twelve-month, reversible metabolic intervention. Private in the UK, not NHS-commissioned. We explain what it does, what it does not, and who it fits.
Why patients choose us
- 01
A consultant bariatric endoscopist, in a proper unit
The endoluminal sleeve is a specialist device. We only refer to endoscopists with device-specific training and a fluoroscopy-equipped list.
- 02
Honest about the evidence
EndoBarrier is not NICE-approved for NHS commissioning. It sits between medical therapy and bariatric surgery — we say so plainly before you commit.
- 03
Independent, and free
We are paid by no clinic, so the recommendation is impartial and costs you nothing.
Indicative pricing
What an endoluminal sleeve costs privately in the UK.
Indicative ranges across our partner units. Send the details and we quote firm figures across two or three options — including full twelve-month packages.
In short
A full twelve-month EndoBarrier package in our network: £12,000–£18,000, self-pay only.
| Procedure | Indicative range | Typical duration | Stay |
|---|---|---|---|
| Endoluminal sleeve (EndoBarrier) — insertion | £8,000–£12,000 | 45–60 min GA | Same day / overnight |
| Endoluminal sleeve — removal at 12 months | £2,500–£4,500 | 30–45 min GA | Same day |
| Full package (insertion, follow-up, removal) | £12,000–£18,000 | 12-month care | End-to-end |
| Duodenal mucosal resurfacing (Revita DMR) | £6,000–£10,000 | 60 min GA | Same day |
| Bariatric consultation only | £250–£450 | 45 min | Same visit |
| Dietitian follow-up (per session) | £120–£220 | 45 min | Same visit |
Prices vary by unit, by whether the quote covers device only or the full twelve-month care package, and by the anaesthetic and imaging setup. UK insurers do not typically cover EndoBarrier — it is a self-pay procedure. We confirm firm figures within one working day.
The problem
A middle option between medication and bariatric surgery.
The endoluminal sleeve is often promoted as a magic bullet. It is not. It is a specialist, twelve-month, reversible metabolic device with real benefits and real risks — and we set out both before you decide.
-
Between drugs and surgery
A twelve-month, reversible intervention for T2DM when GLP-1s are not enough and a permanent bypass or sleeve is too big a step.
-
Not NHS-commissioned
NICE IPG471 (2013) restricts NHS use to research. In the UK this is a private, self-pay route — we say so up front.
-
Plan for month thirteen
Removal is mandatory at twelve months. Without a follow-on plan, roughly half the weight lost is regained.
The journey
From enquiry to removal — what happens across twelve months.
One coordinated team from first message to the removal date — and beyond.
Phase 1 · Before insertion
Concierge, off-stage for you
Phase 2 · Insertion day
A day at the unit
Phase 3 · Twelve months
Follow-up and removal
- 01
Before
You tell us what is going on
A short, confidential form. Your BMI, HbA1c, current diabetes medication and what you have already tried.
- 02
Before
We come back with a recommendation
Within one working day: whether an endoluminal sleeve, a GLP-1, ESG or bariatric surgery fits best — and an indicative price.
- 03
Before
Multidisciplinary workup
Bloods, a dietitian review and a consultant appointment. NSAIDs must be stopped — this is non-negotiable while the device is in place.
- 04
On the day
Arrival at the endoscopy unit
Admission, consent and a chat with the endoscopist and anaesthetist. General anaesthetic with fluoroscopic guidance.
- 05
On the day
The insertion itself
45 to 60 minutes. The 60cm liner is anchored at the duodenal bulb endoscopically, position confirmed under X-ray.
- 06
On the day
Home the same day or overnight
Most patients go home the same day on a liquid diet. Some clinics prefer an overnight stay for observation.
- 07
After
Twelve months, then removal
Dietitian and clinician reviews through the year. Removal is mandatory at twelve months — the device is not a permanent implant.
Typical timeline: 3–6 weeks from enquiry to insertion. Device dwell time: 12 months, mandatory removal.
When it helps
When an endoluminal sleeve is worth considering.
The situations we see most, plus the one red flag that means an emergency rather than an appointment.
-
Type 2 diabetes with obesity (BMI 30–45)
The primary indication. Poorly controlled T2DM on oral agents where a metabolic — not purely bariatric — intervention is wanted.
-
HbA1c that will not settle
Persistent HbA1c above target despite metformin, SGLT2 inhibitors or a GLP-1. Reported reductions of 1.5–2.0% at twelve months.
-
A bridge, not a destination
For patients not ready for a Roux-en-Y or sleeve gastrectomy — a twelve-month reversible intervention that borrows bypass physiology.
-
GLP-1 intolerance or plateau
When semaglutide or tirzepatide caused unmanageable side-effects, or the response has plateaued and further options are needed.
-
Weight loss goal 10–20% TBW
Realistic total body weight loss over twelve months. Not comparable to sleeve gastrectomy or bypass — worth being honest about upfront.
-
Willing to stop all NSAIDs
Ibuprofen, naproxen, aspirin and similar drugs must stop. Anchor-site erosion risk rises sharply without this.
-
Not a first-line choice
NICE IPG471 (2013) restricted this to research. It is a private, self-pay option in the UK — not commissioned by the NHS.
-
Red flag: abdominal pain and fever
Severe pain, fever or jaundice during the twelve months is not normal. Hepatic abscess is the most serious historical complication — same-day A&E.
Related options
EndoBarrier is not the only option.
What each option involves, and which fits which patient — set out honestly, not as a sales page.
-
Endoluminal sleeve (EndoBarrier)
A 60cm impermeable fluoropolymer liner anchored at the duodenal bulb. Food bypasses the proximal small bowel for twelve months, mimicking bypass anatomy.
-
Endoscopic sleeve gastroplasty (ESG)
A separate procedure — stitches inside the stomach to reduce its size. Different mechanism, different indications. See our ESG page.
-
Duodenal mucosal resurfacing (Revita)
Investigational ablation of the duodenal lining to reset metabolic signalling. Trial data in T2DM is promising but not routine UK care.
-
GLP-1 receptor agonists
Semaglutide or tirzepatide — the first-line pharmacological option for T2DM with obesity. Often tried before considering an endoluminal device.
-
Sleeve gastrectomy
Bariatric surgery — a permanent reduction in stomach size. Larger, more durable weight loss but not reversible.
-
Roux-en-Y gastric bypass
The surgical bypass the endoluminal sleeve tries to mimic. Longer track record for T2DM remission but a bigger operation with more risk.
-
Intragastric balloon (Elipse)
A swallowed balloon that sits in the stomach for four to six months. A different mechanism — restriction, not bypass — often confused with EndoBarrier.
-
Consultation only
An honest discussion of what a metabolic endoscopic device can and cannot do — and whether it fits your case at all.
Our vetted UK network
A small panel of bariatric endoscopists, we picked them.
Only units with device-specific training, fluoroscopy on the list and hepatobiliary cover. Not listed publicly — introductions are made privately, once we understand your case.
Selection criteria
How we choose every endoscopist in our network.
-
Consultant bariatric endoscopists with device-specific EndoBarrier training
-
Fluoroscopy-equipped endoscopy lists and hepatobiliary cover
-
Multidisciplinary team — endocrinologist, dietitian, bariatric surgeon
-
Twelve-month care package with a defined removal date, not open-ended
Safety and evidence
What to expect — honestly.
This is a specialist device with a real complication profile. The evidence base is limited, and NICE has not approved it for NHS commissioning. Careful selection, no NSAIDs and mandatory removal at twelve months are the safeguards that matter.
-
GA with fluoroscopy
Insertion is under general anaesthetic with X-ray guidance to confirm the anchor sits correctly at the duodenal bulb.
-
Twelve months is the hard limit
The device must come out at twelve months. Leaving it longer is not an option — this is a temporary, reversible intervention.
-
No NSAIDs, at all
Ibuprofen, naproxen, aspirin and similar drugs must stop for the full twelve months. Anchor-site erosion is the main mechanism of harm here.
-
Hepatic abscess — the historical concern
A rare but serious complication that led to the earlier withdrawal of EndoBarrier. Reworked anchoring and stricter selection have reduced but not eliminated the risk.
-
GI bleeding, migration, obstruction
Sleeve migration, small-bowel obstruction, anchor-site bleeding and pancreatitis are all recognised complications requiring urgent endoscopy.
-
Diet is liquid then soft, then normal
Liquid for the first week, soft for the second, then a modified normal diet. Dietitian input across the twelve months is part of the package.
-
HbA1c response is real but variable
Trial data suggests HbA1c falls by roughly 1.5–2.0% and total body weight by 10–20% at twelve months — but individual responses vary widely.
-
Weight regain after removal is common
Roughly half of weight lost is regained within a year of removal unless GLP-1 therapy or surgery follows. Plan for what happens next before insertion.
-
Red flags
Severe abdominal pain, persistent vomiting, black stools, fever or jaundice are not normal — same-day A&E, and tell them a duodenal-jejunal bypass liner is in place.
Reading your procedure note
Your procedure note in four parts. Read the last one first.
Whichever unit does the insertion, the note the endoscopist sends you keeps to the same shape.
A quiet reminder
Endoscopic language is precise and can read coldly — we translate it for you.
If you would like us to talk you through the note before your dietitian review, just ask.
- 01 Header
Indication and device details
Why the device was chosen — usually T2DM with BMI 30–45 — plus the device batch, sleeve length and anchor position on fluoroscopy.
- 02 Technique
Insertion technique and imaging
How the anchor was seated at the duodenal bulb, fluoroscopy findings, and any difficulty encountered during deployment.
- 03 Findings
Duodenal anatomy and incidental findings
Notes on the stomach and duodenum, ulcers, H. pylori status, and any incidental findings that change monitoring during the twelve months.
- 04 Impression
Diet, medication, review and removal date
Read this first: your liquid-to-solid diet timeline, the medications to stop (all NSAIDs) or adjust (insulin, sulfonylureas), your review dates and the fixed removal date.
Recognised by major UK insurers
UK private medical insurers do not typically cover the endoluminal sleeve — it is treated as an investigational metabolic procedure and paid for privately. We confirm cover in writing before booking.
Frequently asked
Everything we get asked about the endoluminal sleeve.
Quick answers on evidence, cost, complications, and what happens after removal.
-
What is an endoluminal sleeve and how is it different from ESG?
The endoluminal sleeve (EndoBarrier) is a 60cm impermeable liner anchored at the duodenal bulb — food passes through it and bypasses the proximal small bowel for twelve months, mimicking gastric bypass physiology. Endoscopic sleeve gastroplasty (ESG) is a completely different procedure: stitches inside the stomach reduce its size. They are not interchangeable.
-
Is EndoBarrier approved by NICE for the NHS?
No. NICE guidance IPG471 (2013) restricted the duodenal-jejunal bypass liner to use within research protocols on the NHS. It regained a CE mark in the EU in 2023 and is available privately in the UK, but it is not routinely commissioned by the NHS.
-
Who is it for — weight loss or diabetes?
Primarily for adults with type 2 diabetes and obesity (BMI 30–45) where better glycaemic control is the main goal. Weight loss of 10–20% total body weight is a welcome secondary effect, not the headline. If your goal is pure weight loss, ESG, sleeve gastrectomy or a GLP-1 will usually be a better fit.
-
How much does an endoluminal sleeve cost privately in the UK?
Roughly £8,000–£12,000 for insertion alone, £2,500–£4,500 for removal, and £12,000–£18,000 for a full twelve-month package including follow-up and dietitian support. Duodenal mucosal resurfacing (Revita DMR) sits at £6,000–£10,000 where available.
-
What are the main complications?
The historical concern that led to the earlier withdrawal was hepatic abscess. Other recognised complications include GI bleeding, sleeve migration, small-bowel obstruction, anchor-site erosion and pancreatitis. This is why NSAIDs must stop and why the twelve-month removal is not negotiable.
-
What happens after the device comes out?
Roughly half of weight lost is typically regained within a year of removal unless a follow-on strategy is in place — usually GLP-1 therapy, bariatric surgery, or a structured dietitian-led programme. The insertion decision should include a plan for what happens at month thirteen.
-
What is duodenal mucosal resurfacing (Revita)?
DMR is an investigational endoscopic ablation of the duodenal lining, designed to reset metabolic signalling in T2DM. Early trial data is promising but it is not routine UK care. We can flag centres running trials or offering it as a private option, but the evidence bar is lower than for established bariatric procedures.
Nearby in the library